📊 SION Key Takeaways
Is Sionna Therapeutics, Inc. (SION) a Good Investment?
Sionna Therapeutics is a pre-commercial stage biopharmaceutical company with zero revenue and annual operating cash burn of $66.3M. With only $58.5M in cash reserves and no debt, the company has approximately 10-11 months of runway at current burn rates, creating significant near-term refinancing risk. While the improving loss trajectory is encouraging, the lack of revenue, limited cash runway, and high execution risk inherent in drug development present substantial downside risk.
Why Buy Sionna Therapeutics, Inc. Stock? SION Key Strengths
- Pristine balance sheet with no long-term debt and minimal liabilities ($19.1M)
- Excellent liquidity position with 20.61x current ratio providing near-term operational stability
- Improving loss profile with net losses down 22% YoY, indicating potential progress toward commercialization
SION Stock Risks: Sionna Therapeutics, Inc. Investment Risks
- Pre-commercial stage with zero revenue and no clear path to near-term revenue generation
- Severe cash burn of $66.3M annually with only ~10-11 months of cash runway, requiring dilutive capital raise
- High execution risk typical of biopharmaceutical companies with dependence on clinical trial success and regulatory approval
Key Metrics to Watch
- Quarterly operating cash burn rate and cash runway extension timeline
- Clinical trial progress, regulatory milestones, and potential catalysts for product approval
- Capital raising activity and dilution impact on shareholder equity
Sionna Therapeutics, Inc. (SION) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 20.61x current ratio provides a solid financial cushion.
SION Profit Margin, ROE & Profitability Analysis
SION vs Healthcare Sector: How Sionna Therapeutics, Inc. Compares
How Sionna Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sionna Therapeutics, Inc. Stock Overvalued? SION Valuation Analysis 2026
Based on fundamental analysis, Sionna Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sionna Therapeutics, Inc. Balance Sheet: SION Debt, Cash & Liquidity
SION Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sionna Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-15.99 indicates the company is currently unprofitable.
SION Revenue Growth, EPS Growth & YoY Performance
Sionna Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
SION SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sionna Therapeutics, Inc. (CIK: 0002036042)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SION
What is the AI rating for SION?
Sionna Therapeutics, Inc. (SION) has an AI rating of SELL with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SION's key strengths?
Claude: Pristine balance sheet with no long-term debt and minimal liabilities ($19.1M). Excellent liquidity position with 20.61x current ratio providing near-term operational stability.
What are the risks of investing in SION?
Claude: Pre-commercial stage with zero revenue and no clear path to near-term revenue generation. Severe cash burn of $66.3M annually with only ~10-11 months of cash runway, requiring dilutive capital raise.
What is SION's revenue and growth?
Sionna Therapeutics, Inc. reported revenue of N/A.
Does SION pay dividends?
Sionna Therapeutics, Inc. does not currently pay dividends.
Where can I find SION SEC filings?
Official SEC filings for Sionna Therapeutics, Inc. (CIK: 0002036042) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SION's EPS?
Sionna Therapeutics, Inc. has a diluted EPS of $-1.88.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SION a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Sionna Therapeutics, Inc. has a SELL rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SION stock overvalued or undervalued?
Valuation metrics for SION: ROE of -24.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SION stock in 2026?
Our dual AI analysis gives Sionna Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SION's free cash flow?
Sionna Therapeutics, Inc.'s operating cash flow is $-66.3M, with capital expenditures of $377.0K.
How does SION compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -24.5% (avg: 15%), current ratio 20.61 (avg: 2).